BAAT: Enzyme Breakdown Fatty Acids (G570)

Target Name: BAAT

NCBI ID: G570

BAAT

BAAT: Enzyme Breakdown Fatty Acids

The long-chain fatty-acyl-CoA hydrolase (BAAT) is a enzyme that plays a crucial role in the metabolism of fatty acids in the body. It is an essential enzyme that helps to break down fatty acids, particularly those found in the blood, into simpler sugars that can be used by the body for energy. BAAT is found in various tissues throughout the body and is responsible for breaking down fatty acids in the bloodstream.

BAAT's role in the body

BAAT is an enzyme that is involved in the breakdown of fatty acids into simpler sugars. It is a critical enzyme that helps to keep the body's fatty acid levels in check. When the body's levels of fatty acids become too high, BAAT helps to break them down into simpler sugars, which can then be used by the body for energy.

BAAT's role in disease

BAAT is also involved in the regulation of fatty acid levels in the body. When there is a problem with the body's ability to break down fatty acids, such as in the case of fatty liver disease, BAAT may play a crucial role in the development and progression of the disease.

BAAT's potential as a drug target

The discovery of BAAT as a potential drug target has significant implications for the treatment of various diseases. The ability to target BAAT with small molecules has the potential to be a highly effective therapy for a range of conditions, including fatty liver disease, diabetes, and obesity.

BAAT's role in fatty liver disease

Fatty liver disease is a common condition that affects millions of people worldwide. It is characterized by the buildup of fat in the liver, which can lead to the development of a range of health problems. In some cases, fatty liver disease can be caused by a genetic mutation that results in the buildup of fat in the liver. In other cases, it can be caused by obesity, untreated diabetes, or other factors.

BAAT's role in the development and progression of fatty liver disease is not well understood. However, studies have shown that BAAT is involved in the regulation of fatty acid levels in the liver. It has been shown that changes in BAAT activity can contribute to the development and progression of fatty liver disease.

BAAT's potential as a drug target

The discovery of BAAT as a potential drug target has significant implications for the treatment of fatty liver disease. By targeting BAAT with small molecules, researchers may be able to develop new treatments for this disease.

BAAT's potential as a biomarker

BAAT is also an enzyme that has the potential to serve as a biomarker for fatty liver disease. The buildup of fat in the liver can be detected by measuring the levels of BAAT in the liver. By measuring the levels of BAAT in the liver, researchers may be able to monitor the progress of fatty liver disease and the effectiveness of new treatments.

Conclusion

BAAT is an enzyme that plays a crucial role in the metabolism of fatty acids in the body. It is an essential enzyme that helps to break down fatty acids into simpler sugars that can be used by the body for energy. The discovery of BAAT as a potential drug target and biomarker has significant implications for the treatment of various diseases, including fatty liver disease. Further research is needed to fully understand the role of BAAT in the body and its potential as a drug target and biomarker.

Protein Name: Bile Acid-CoA:amino Acid N-acyltransferase

Functions: Catalyzes the amidation of bile acids (BAs) with the amino acids taurine and glycine (PubMed:12810727, PubMed:8034703, PubMed:2037576, PubMed:12239217). More than 95% of the BAs are N-acyl amidates with glycine and taurine (PubMed:8034703). Amidation of BAs in the liver with glycine or taurine prior to their excretion into bile is an important biochemical event in bile acid metabolism (PubMed:12810727). This conjugation (or amidation) plays several important biological roles in that it promotes the secretion of BAs and cholesterol into bile and increases the detergent properties of BAs in the intestine, which facilitates lipid and vitamin absorption (PubMed:12810727). May also act as an acyl-CoA thioesterase that regulates intracellular levels of free fatty acids (PubMed:12810727, PubMed:8034703, PubMed:12239217). In vitro, catalyzes the hydrolysis of long- and very long-chain saturated acyl-CoAs to the free fatty acid and coenzyme A (CoASH), and conjugates glycine to these acyl-CoAs (PubMed:12810727)

The "BAAT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAAT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets